This non-clinical study shows that the gedatolisib/fulvestrant/palbociclib triplet exerted greater growth inhibitory effects than the single agents or the palbociclib/fulvestrant doublet by inhibiting multiple cellular functions in BC cells, regardless of their PIK3CA/PTEN mutational status. The gene discussed is PIK3CA; the disease is breast cancer.